Search Results - "Yang, James C"

Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations by Paik, Paul K, Felip, Enriqueta, Veillon, Remi, Sakai, Hiroshi, Cortot, Alexis B, Garassino, Marina C, Mazieres, Julien, Viteri, Santiago, Senellart, Helene, Van Meerbeeck, Jan, Raskin, Jo, Reinmuth, Niels, Conte, Pierfranco, Kowalski, Dariusz, Cho, Byoung Chul, Patel, Jyoti D, Horn, Leora, Griesinger, Frank, Han, Ji-Youn, Kim, Young-Chul, Chang, Gee-Chen, Tsai, Chen-Liang, Yang, James C.-H, Chen, Yuh-Min, Smit, Egbert F, van der Wekken, Anthonie J, Kato, Terufumi, Juraeva, Dilafruz, Stroh, Christopher, Bruns, Rolf, Straub, Josef, Johne, Andreas, Scheele, Jürgen, Heymach, John V, Le, Xiuning

“…In a study involving patients with non–small-cell lung cancer with a MET exon 14 skipping mutation, the use of tepotinib (a selective MET inhibitor) was…”
Get full text

Toxicities of Immunotherapy for the Practitioner by Weber, Jeffrey S, Yang, James C, Atkins, Michael B, Disis, Mary L

“…The toxicities of immunotherapy for cancer are as diverse as the type of treatments that have been devised. These range from cytokine therapies that induce…”
Get full text

First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases by Schuler, Martin, Wu, Yi-Long, Hirsh, Vera, O'Byrne, Kenneth, Yamamoto, Nobuyuki, Mok, Tony, Popat, Sanjay, Sequist, Lecia V, Massey, Dan, Zazulina, Victoria, Yang, James C-H

“…Metastatic spread to the brain is common in patients with non-small cell lung cancer (NSCLC), but these patients are generally excluded from prospective…”
Get more information

Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients by Gros, Alena, Parkhurst, Maria R, Tran, Eric, Pasetto, Anna, Robbins, Paul F, Ilyas, Sadia, Prickett, Todd D, Gartner, Jared J, Crystal, Jessica S, Roberts, Ilana M, Trebska-McGowan, Kasia, Wunderlich, John R, Yang, James C, Rosenberg, Steven A

“…Steven Rosenberg and colleagues report that PD-1 is a biomarker of CD8 + T cells in the blood that recognize mutated neoantigens in melanoma. Detection of…”
Get full text

PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors by Gros, Alena, Robbins, Paul F, Yao, Xin, Li, Yong F, Turcotte, Simon, Tran, Eric, Wunderlich, John R, Mixon, Arnold, Farid, Shawn, Dudley, Mark E, Hanada, Ken-Ichi, Almeida, Jorge R, Darko, Sam, Douek, Daniel C, Yang, James C, Rosenberg, Steven A

“…Adoptive transfer of tumor-infiltrating lymphocytes (TILs) can mediate regression of metastatic melanoma; however, TILs are a heterogeneous population, and…”
Get full text

CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors by Jin, Linchun, Tao, Haipeng, Karachi, Aida, Long, Yu, Hou, Alicia Y., Na, Meng, Dyson, Kyle A., Grippin, Adam J., Deleyrolle, Loic P., Zhang, Wang, Rajon, Didier A., Wang, Qiong J., Yang, James C., Kresak, Jesse L., Sayour, Elias J., Rahman, Maryam, Bova, Frank J., Lin, Zhiguo, Mitchell, Duane A., Huang, Jianping

“…Chimeric antigen receptor (CAR) T-cell therapy targeting solid tumors has stagnated as a result of tumor heterogeneity, immunosuppressive microenvironments,…”
Get full text

A Phase II Study of Tumor-infiltrating Lymphocyte Therapy for Human Papillomavirus-associated Epithelial Cancers by Stevanović, Sanja, Helman, Sarah R, Wunderlich, John R, Langhan, Michelle M, Doran, Stacey L, Kwong, Mei Li M, Somerville, Robert P T, Klebanoff, Christopher A, Kammula, Udai S, Sherry, Richard M, Yang, James C, Rosenberg, Steven A, Hinrichs, Christian S

“…Cellular therapy is an emerging cancer treatment modality, but its application to epithelial cancers has been limited. This clinical trial evaluated…”
Get full text

Adoptive cell transfer: a clinical path to effective cancer immunotherapy by Rosenberg, Steven A, Restifo, Nicholas P, Yang, James C, Morgan, Richard A, Dudley, Mark E

“…Key Points Adoptive cell therapy (ACT) is a treatment that uses a cancer patient's own T lymphocytes with anti-tumour activity, expanded in vitro and reinfused…”
Get full text

Efficacy of Adjuvant Radiation Therapy in the Treatment of Soft Tissue Sarcoma of the Extremity: 20-year Follow-Up of a Randomized Prospective Trial by Beane, Joal D., Yang, James C., White, Donald, Steinberg, Seth M., Rosenberg, Steven A., Rudloff, Udo

“…Background This update of a randomized, prospective study presents the effect of external beam radiation therapy (EBRT) on long-term overall survival, local…”
Get full text

Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer by Ramalingam, Suresh S, Yang, James C-H, Lee, Chee Khoon, Kurata, Takayasu, Kim, Dong-Wan, John, Thomas, Nogami, Naoyuki, Ohe, Yuichiro, Mann, Helen, Rukazenkov, Yuri, Ghiorghiu, Serban, Stetson, Daniel, Markovets, Aleksandra, Barrett, J Carl, Thress, Kenneth S, Jänne, Pasi A

“…Purpose The AURA study ( ClinicalTrials.gov identifier: NCT01802632) included two cohorts of treatment-naïve patients to examine clinical activity and safety…”
Get full text

Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study by Chandran, Smita S, PhD, Somerville, Robert P T, PhD, Yang, James C, MD, Sherry, Richard M, MD, Klebanoff, Christopher A, MD, Goff, Stephanie L, MD, Wunderlich, John R, MD, Danforth, David N, MD, Zlott, Daniel, PharmD, Paria, Biman C, PhD, Sabesan, Arvind C, MD, Srivastava, Abhishek K, PhD, Xi, Liqiang, PhD, Pham, Trinh H, MS, Raffeld, Mark, MD, White, Donald E, MS, Toomey, Mary Ann, BSN, Rosenberg, Steven A, MD, Kammula, Udai S, Dr

“…Summary Background Uveal melanoma is a rare tumour with no established treatments once metastases develop. Although a variety of immune-based therapies have…”
Get full text

Recognition of human gastrointestinal cancer neoantigens by circulating PD-1+ lymphocytes by Gros, Alena, Tran, Eric, Parkhurst, Maria R, Ilyas, Sadia, Pasetto, Anna, Groh, Eric M, Robbins, Paul F, Yossef, Rami, Garcia-Garijo, Andrea, Fajardo, Carlos A, Prickett, Todd D, Jia, Li, Gartner, Jared J, Ray, Satyajit, Ngo, Lien, Wunderllich, John R, Yang, James C, Rosenberg, Steven A

“…Tumor-resident lymphocytes can mount a response against neoantigens expressed in microsatellite-stable gastrointestinal (GI) cancers, and adoptive transfer of…”
Get full text

Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial by Camidge, D Ross, Kim, Hye Ryun, Ahn, Myung-Ju, Yang, James C H, Han, Ji-Youn, Hochmair, Maximilian J, Lee, Ki Hyeong, Delmonte, Angelo, García Campelo, Maria Rosario, Kim, Dong-Wan, Griesinger, Frank, Felip, Enriqueta, Califano, Raffaele, Spira, Alexander, Gettinger, Scott N, Tiseo, Marcello, Lin, Huamao M, Gupta, Neeraj, Hanley, Michael J, Ni, Quanhong, Zhang, Pingkuan, Popat, Sanjay

“…Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor, demonstrated superior progression-free survival (PFS) and improved health-related…”
Get full text

Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1 by ROBBINS, Paul F, MORGAN, Richard A, KAMMULA, Udai S, HUGHES, Marybeth S, RESTIFO, Nicholas P, RAFFELD, Mark, LEE, Chyi-Chia Richard, LEVY, Catherine L, LI, Yong F, EL-GAMIL, Mona, SCHWARZ, Susan L, LAURENCOT, Carolyn, FELDMAN, Steven A, ROSENBERG, Steven A, YANG, James C, SHERRY, Richard M, DUDLEY, Mark E, WUNDERLICH, John R, NAHVI, Azam V, HELMAN, Lee J, MACKALL, Crystal L

“…Adoptive immunotherapy using tumor-infiltrating lymphocytes represents an effective cancer treatment for patients with metastatic melanoma. The NY-ESO-1…”
Get full text

Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma by ROYAL, Richard E, LEVY, Catherine, ROSENBERG, Steven A, TURNER, Keli, MATHUR, Aarti, HUGHES, Marybeth, KAMMULA, Udai S, SHERRY, Richard M, TOPALIAN, Suzanne L, YANG, James C, LOWY, Israel

“…New, effective therapies are needed for pancreatic ductal adenocarcinoma. Ipilimumab can mediate an immunologic tumor regression in other histologies. This…”
Get full text

Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy by Morgan, Richard A, Chinnasamy, Nachimuthu, Abate-Daga, Daniel, Gros, Alena, Robbins, Paul F, Zheng, Zhili, Dudley, Mark E, Feldman, Steven A, Yang, James C, Sherry, Richard M, Phan, Giao Q, Hughes, Marybeth S, Kammula, Udai S, Miller, Akemi D, Hessman, Crystal J, Stewart, Ashley A, Restifo, Nicholas P, Quezado, Martha M, Alimchandani, Meghna, Rosenberg, Avi Z, Nath, Avindra, Wang, Tongguang, Bielekova, Bibiana, Wuest, Simone C, Akula, Nirmala, McMahon, Francis J, Wilde, Susanne, Mosetter, Barbara, Schendel, Dolores J, Laurencot, Carolyn M, Rosenberg, Steven A

“…Nine cancer patients were treated with adoptive cell therapy using autologous anti-MAGE-A3 T-cell receptors (TCR)-engineered T cells. Five patients experienced…”
Get full text

Using patient-derived tumor organoids from common epithelial cancers to analyze personalized T-cell responses to neoantigens by Parikh, Anup Y., Masi, Robert, Gasmi, Billel, Hanada, Ken-ichi, Parkhurst, Maria, Gartner, Jared, Sindiri, Sivasish, Prickett, Todd, Robbins, Paul, Zacharakis, Nikolaos, Beshiri, Mike, Kelly, Kathleen, Rosenberg, Steven A., Yang, James C.

“…Adoptive cell transfer of tumor-infiltrating lymphocytes (TIL) can mediate durable complete responses in some patients with common epithelial cancers but does…”
Get full text

Preclinical Evaluation of Chimeric Antigen Receptors Targeting CD70-Expressing Cancers by Wang, Qiong J, Yu, Zhiya, Hanada, Ken-Ichi, Patel, Krishna, Kleiner, David, Restifo, Nicholas P, Yang, James C

“…CD70 expression in normal tissues is restricted to activated lymphoid tissues. Targeting CD70 on CD70-expressing tumors could mediate "on-target, off-tumor"…”
Get full text

Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens by DUDLEY, Mark E, YANG, James C, WUNDERLICH, John, RESTIFO, Nicholas P, THOMASIAN, Armen, DOWNEY, Stephanie G, SMITH, Franz O, KLAPPER, Jacob, MORTON, Kathleen, LAURENCOT, Carolyn, WHITE, Donald E, ROSENBERG, Steven A, SHERRY, Richard, HUGHES, Marybeth S, ROYAL, Richard, KAMMULA, Udai, ROBBINS, Paul F, JIANPING HUANG, CITRIN, Deborah E, LEITMAN, Susan F

“…The two approved treatments for patients with metastatic melanoma, interleukin (IL)-2 and dacarbazine, mediate objective response rates of 12% to 15%. We…”
Get full text

Cancer immunotherapy: moving beyond current vaccines by Rosenberg, Steven A, Yang, James C, Restifo, Nicholas P

“…Great progress has been made in the field of tumor immunology in the past decade, but optimism about the clinical application of currently available cancer…”
Get full text